LOS ANGELES, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Nevro Corp. (NYSE: NVRO) (“Nevro” or “the Company”) and whether the Company’s officers and directors complied with their legal obligations to the Company and its shareholders.

In April 2017, Boston Scientific Corp. filed an action against Nevro, asserting claims of patent infringement, theft of trade secrets and tortious interference with contract by recruiting and hiring dozens of former Boston Scientific Corp. employees.

Then, on July 10, 2018, various analysts reported on a tentative ruling in Nevro’s patent litigation against Boston Scientific. The tentative ruling invalidated at least five of the patents related to Nevro’s purportedly “proprietary” HF10 therapy and Senza systems.

GPM’s investigation focuses on whether the Company and its directors breached any fiduciary duties owed to shareholders.

If you own Nevro shares, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:
Glancy, Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com